FDA warnt vor Leberversagen und Tod unter Hepatitis-C-Medikamenten – für einige Patientengruppen nicht ratsam  Die US-Arzneimittelbehörde FDA warnt vor schweren Leberschäden bei Patienten, die mit den Kombinationspräparaten Glecaprevir-Pibrent…

Hepatitis C virus in people who inject drugs (PWID): Regional Webinar Watch Professor Graham Foster, Mr Duncan Hill, Dr Cyrus Abbasian and Dr Professor Rosmawati Mohamed in this expert discussion exploring Hepatitis C virus in PWID in Asia and Euro…

Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population. Simon TG, Duberg AS, Aleman S, Hagstrom H, Nguyen LH, Khalili H, Chung RT, Ludvigsson JF. An…

Hepatitis B and C prevalence and incidence in key population groups with multiple risk factors in the EU/EEA: a systematic review. Mason LM, Duffell E, Veldhuijzen IK, Petriti U, Bunge EM, Tavoschi L. Euro Surveill. 2019 Jul;24(30). doi: 10.2807/1…

Sociodemographic and clinical characteristics of persons who experienced spontaneous hepatitis C viral clearance. Kimble MM, Javanbakht M, Chew KW, Stafylis C, He D, Ramirez S, Baik Y, Saab S, Klausner JD. BMC Infect Dis. 2019 Jul 15;19(1):626. do…

HCV Extrahepatic Manifestations. Kuna L, Jakab J, Smolic R, Wu GY, Smolic M. J Clin Transl Hepatol. 2019 Jun 28;7(2):172-182. doi: 10.14218/JCTH.2018.00049.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609844/